Pathology . J Mol Diagn 2006 ; 8 : 412 – 419 . 12. Maxson JE Gotlib J Pollyea DA . Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML . N Engl J Med 2013 ; 368 : 1781 – 1790 . 13. Piazza R Valletta S
Search Results
Brady L. Stein, Susan O’Brien, Peter Greenberg, and Ruben A. Mesa
Louis Burt Nabors
complete all of the prescribed cycles of chemotherapy,” revealed Dr. Nabors. Based on the findings of both RTOG 9402 and EORTC 26951, the adjuvant treatment pathway in the 2015 NCCN Guidelines for CNS Cancers hinges on the pathology results of the
Dipesh Uprety and David E. Marinier
used for concurrent CRT, including cisplatin/etoposide, carboplatin/paclitaxel, cisplatin/vinblastine, and, for nonsquamous pathology, carboplatin or cisplatin with pemetrexed. 7 The carboplatin/paclitaxel regimen is given weekly with radiation therapy
Grant A. McArthur
. Chromogenic in situ hybridization and FISH in pathology . Methods Mol Biol 2002 ; 204 : 343 – 351 . 8. Haycox CL Odland PB Olbricht SM Piepkorn M . Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical
Brian Vicuna and Al B. Benson III
: 65 – 69 . 15. Morris E Maughan NJ Forman D Quirke P . Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? – The need for high quality pathology . Gut 2007 ; 56 : 1419 – 1425 . 16. Soreide K Janssen EA
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead
developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer–focused expertise in the fields of medical, surgical, and radiation oncology and pathology, reconstructive surgery, and patient advocacy. This
Kilian E. Salerno
Neoadjuvant Treatment Following neoadjuvant chemotherapy, indications for RT should be guided by maximal disease stage from either prechemotherapy tumor characteristics at diagnosis or postchemotherapy pathology results. Patients with residual nodal disease
Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Nicholas Butowski, Robert A. Fenstermaker, Peter Forsyth, Jona Hattangadi-Gluth, Matthias Holdhoff, Steven Howard, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Paul L. Moots, Maciej M. Mrugala, Seema Nagpal, Manjari Pandey, Ian Parney, Katherine Peters, Vinay K. Puduvalli, John Ragsdale III, Jason Rockhill, Lisa Rogers, Chad Rusthoven, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, Christina Tsien, Stephanie Weiss, Patrick Yung Wen, Nicole Willmarth, Mary Anne Bergman, and Anita Engh
Pathology” (see BRAIN-F, pages 1334 and 1335) to provide background and recommendations for histologic characterization and molecular testing for gliomas. This article also describes data from clinical trials with available molecular information that have
Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes
kidney, hydronephrosis, metanephric tumors (ie, adenoma, stromal tumor, adenofibroma), multicystic kidney disease, polycystic kidney disease, renal hemorrhage, and renal vein thrombosis. Pathology To avoid potential tumor spread from malignant
David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology . Arch Pathol Lab Med
